Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: Results from the ROCnRAL ANRS 157 study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1648-1652

  Katlama, Christine ^a,b,c   Assoumou, Lambert ^a,b   Valantin, Marc Antoine ^a,b,c   Soulié, Cathia ^a,b,c   Duvivier, Claudine ^d   Chablais, Laetitia ^a,b   Kolta, Sami ^e   Pialoux, Gilles ^f   Mercié, Patrick ^e   Simon, Anne ^b,c   Costagliola, Dominique ^a,b   Peytavin, Gilles ^g   Marcelin, Anne Genevieve ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL TENON   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

Lipodystrophy; Nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; RALTEGRAVIR; TRIACYLGLYCEROL; VIRUS DNA; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPOHYPERTROPHY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); RASH; SIDE EFFECT; TREATMENT RESPONSE; VIREMIA; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS RESISTANCE; CLINICAL TRIAL; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPODYSTROPHY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RISK FACTOR; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PYRROLIDINONES; RISK FACTORS; TREATMENT FAILURE; TRIAZOLES; VIRAL LOAD;

EID: 84903396372     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt536     Document Type: Article

References (20)

1. Phillips AN, Leen C, Wilson A et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370: 1923-8.
2. Assoumou L, Katlama C, Viard JP et al. Changes in bone mineral density over a two-year period in HIV-1-infected men under cART with osteopenia. AIDS 2013; 27: 2425-30.
3. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
4. Islam FM, Wu JY, Jansson J et al. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health 2012; 12: 234.
5. Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 1228-30.
6. Nguyen A, Calmy A, Schiffer V et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9: 142-50.
7. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
8. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
9. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
10. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
11. Martinez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
12. Curran A, Martinez E, Saumoy M et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012; 26: 475-81.
13. Soulie C, Fourati S, Lambert-Niclot S et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65: 749-51.
14. Dimonte S, Babakir-Mina M, Aquaro S et al. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naive infected individuals. Infection 2013; 41: 1097-102.
15. Nachega JB, Hsu AJ, Uthman OA et al. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012; 26 Suppl 1: S39-53.
16. Abel S, van der Ryst E, Rosario MC et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 5-18.
17. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-63.
18. Hoy J, Grund B, Roediger M et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART body composition substudy. J Bone Miner Res 2013; 28: 1264-74.
19. Duvivier C, Kolta S, Assoumou L et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23: 817-24.
20. McComsey GA, Kitch D, Daar ES et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-801.